Ameet Mallik - 13 Feb 2026 Form 4 Insider Report for ADC Therapeutics SA (ADCT)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: ADCT
Reported as of: 13 Feb 2026
Net transaction value: +$3,179,108
SEC form: 4
Accepted by SEC: 18 Feb 2026, 17:39:54 UTC
Prior SEC filing: 09 Dec 2025
Next SEC filing: 02 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Lisa Kallebo, as Attorney-in-Fact for Ameet Mallik

Key filing fact

Ameet Mallik filed Form 4 for ADC Therapeutics SA (ADCT) on 18 Feb 2026.

Key facts

This page summarizes Ameet Mallik's Form 4 filing for ADC Therapeutics SA (ADCT).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 18 Feb 2026, 17:39.

Change

Previous filing in this sequence was filed on 09 Dec 2025.
Current net transaction value: +$3,179,108.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001861441 Primary reporting owner

MALLIK AMEET

Relationship: Chief Executive Officer, Director
Address: 430 MOUNTAIN AVE, SUITE 404, NEW PROVIDENCE
Signature: /s/ Lisa Kallebo, as Attorney-in-Fact for Ameet Mallik
Signature date: 18 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ADCT transaction

Common Shares

Award

Transaction value: $3,591,000
Shares: +900,000
Change %: +138%
Price: $3.99
Shares after: 1,550,000
Date: 13 Feb 2026
Ownership: Direct
Footnotes: F1, F2

ADCT transaction

Common Shares

Tax liability

Transaction value: $411,892
Shares: -103,231
Change %: -6.7%
Price: $3.99
Shares after: 1,446,769
Date: 13 Feb 2026
Ownership: Direct
Footnotes: F3

ADCT holding

Common Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 669,101
Date: 13 Feb 2026
Ownership: By grantor retained annuity trust
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents Common Shares to be delivered in settlement of a restricted share unit award which vests one-third on the first anniversary of the grant date, which grant date is February 13, 2026, and then one-third on each anniversary date thereafter, upon continued service through the designated vesting event.

Footnote F2

Balance reflects the prior transfer of 669,101 Common Shares from the Reporting Person to a grantor retained annuity trust, which transfer is exempt from Section 16(b) pursuant to Rule 16a-13. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Footnote F3

Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted.